Thyroid Cancer Drug Market - Trends Forecast Till 2028

Thyroid Cancer Drug Market, By Type (Papillary Thyroid Cancer, Follicular Thyroid Cancer, Hurthle Cell Cancer, Medullary Thyroid Cancer (MTC) and Anaplastic Thyroid Cancer), Treatment (Medication, Chemotherapy, Radioactive Iodine (Radioiodine) Therapy, Hormone Therapy, and Surgery), Drug Type (Thyroid Desiccated, Sorafenib, Thyrotropin Alfa, Vandetanib, Doxorubicin, Cabozantinib, Lenvatini, Sodium Iodide I-131, Dabrafenib, Trametinib, and Others), Route of Administration (Oral, Injectable and Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others) and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa and South America)

Published Date: May, 2021

Base Year Estimate: 2020

Report ID: D-PH-TCDM-153

Format:  

Number of Pages: 387

Domain: Pharmaceutical

Thyroid Cancer Drug Market – Trends Forecast Till 2028

The global Thyroid Cancer Drug market is anticipated to reach USD 3.54 billion in 2021 growing at a CAGR of 21.48% during the forecasting period, 2021-2028.

Thyroid cancer is the cancer of the thyroid gland which is located in the neck region of the human body. It is a butterfly-shaped gland that releases 3 hormones 1.triidothyronine (T3) 2.thyroxin (T4) 3.Calcitonin. The thyroid gland uses iodine from the blood to make these hormones and stores and releases the hormones when required. Proper functioning of the thyroid gland is essential for the normal metabolism of the body.

A recent increase in the cases of thyroid cancer and unhealthy lifestyle contributing to the disease prevalence along with the RD in the sector are some of the factors that have supported long-term expansion for the Thyroid Cancer Drug industry.

Thyroid Cancer Drug Market Research

The global Thyroid Cancer Drug market is segmented into Type, Treatment, Drug Type, Route of Administration, End-Users, and geography.

The type segment is segmented into Papillary Thyroid Cancer, Follicular Thyroid Cancer, Hurthle Cell Cancer, Medullary Thyroid Cancer (MTC), and Anaplastic Thyroid Cancernal Fixators, Braces, and Prosthesis

Treatment segment is segmented into Medication, Chemotherapy, Radioactive Iodine (Radioiodine) Therapy, Hormone Therapy, and Surgery

The end-User segment is segmented into Hospitals, Homecare, Specialty Clinics, Others

The drug type segment is segmented into Thyroid Desiccated, Sorafenib, Thyrotropin Alfa, Vandetanib, Doxorubicin, Cabozantinib, Lenvatini, Sodium Iodide I-131, Dabrafenib, Trametinib, and Others

Route of administration segment is segmented into Oral, Injectable, and Others

Geographically, the global Thyroid Cancer Drug market is sub-segmented into North America, Europe, Asia-Pacific, Middle East, and Africa and South America, and insights are provided for each region and major countries within the regions

Key players in the global Thyroid Cancer Drug market are Mylan N.V., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Jerome Stevens Pharmaceuticals, Inc, Baxter, Abbott, Celgene Corporation, AstraZeneca, GlaxoSmithKline plc, Eisai Co., Ltd, Takeda Pharmaceutical Company Ltd, Biovista, Cytori Therapeutics Inc, Bayer AG, Novartis AG, Bio-Path Holdings, Inc., and Vascular Biogenics among others.

Available Customizations

In addition to the market data for the Thyroid Cancer Drug market, Delvens offers client-centric reports and customized according to the company’s specific demand and requirement.

Research Methodology

Secondary Research

This research method involved the usage of extensive secondary sources (such as directories and databases)—Hoovers, Avention, annual reports, investor presentation, a conference like Jefferies conference)—to identify and collect information useful for this study of the Thyroid Cancer Drug market. The purpose of secondary research was to identify and collection of extensive, technical, market-oriented, and commercial studies of the global Thyroid Cancer Drug market. Through secondary, the market is classified and segmented as per of industry trend, development, regional market. Product and technology development.

Primary Research

The primary sources mainly included several industry experts from the core and related industries and suppliers, manufacturers, distributors, alliances, and organizations related to all segments of this industry’s supply chain. In-depth interviews were conducted with various primary respondents—including key industry participants, subject matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts—to obtain and verify critical qualitative and quantitative information as well as to assess prospects. The following figure depicts the market research methodology used in drafting this report on the Thyroid Cancer Drug market.

The primary Respondent breakdown is given below:

Thyroid Cancer Drug Market Primary Respondents

 

Market Sizing

Top-down and bottom approaches were used to derive the market estimate and validate the total revenue of the Thyroid Cancer Drug market. This approach has also been used to derive the market for segmentation and sub-segmentation.

Data Validation

Impact analysis has been conducted for deriving the market size. After collecting the in-depth quantitative and qualitative data we contact the primary respondent to gain a 98.8% of confidence level on our data.

The data validation involves the primary research from the industry experts belonging to:

  • Leading Companies
  • Suppliers & Distributors
  • Manufacturers
  • Consumers
  • Industry/Strategic Consultants

Reasons to Acquire

  • Increase your understanding of the market for identifying the best and suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors
  • Gain authentic and granular data access for the Thyroid Cancer Drug market to understand the trends and the factors involved in changing market situations
  • Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future
  • In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns

Report Scope

 

Report Feature

Descriptions

Market Revenue In 2021

USD 3.54 billion

Growth Rate

CAGR of 21.48% during the forecasting period, 2021-2028

Historical Data

2018-2019

Forecast Years

2021-2028

Base Year

2020

Units Considered

Revenue in USD billion and CAGR from 2021 to 2028

Report Segmentation

Type, Treatment, Drug Type, Route of Administration, End-Users, and Geography

Report Attribute

Market Revenue Sizing (Global, Regional and Country Level) Company Share Analysis, Market Dynamics, Company Profiling

Regional Level Scope

North America, Europe, Asia-Pacific, South America, and the Middle East and Africa

Country Level Scope

U.S., Japan, Germany, U.K., China, India, Brazil, UAE, South Africa (50+ Countries Across the Globe)

Companies Profiled

Mylan N.V., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Jerome Stevens Pharmaceuticals, Inc, Baxter, Abbott, Celgene Corporation, AstraZeneca, GlaxoSmithKline plc, Eisai Co., Ltd, Takeda Pharmaceutical Company Ltd, Biovista, Cytori Therapeutics Inc, Bayer AG, Novartis AG, Bio-Path Holdings, Inc., And Vascular Biogenics

Available Customization

In addition to the market data for the Thyroid Cancer Drug market, Delvens offers client-centric reports and customized according to the company’s specific demand and requirement.

Please complete the form below:

This website is secure and your personal details are safe. Privacy Policy

Please complete the form below:

This website is secure and your personal details are safe. Privacy Policy

Please complete the form below:

This website is secure and your personal details are safe. Privacy Policy

Choose License Type
Global: 50+ Countries

Note: Report data and information will be by Country.


Regional Report

Note: Report data and information will be by Country.


Country Specific Report

Bundle Reports

50% Discount on all additional reports  

Special Pricing

Avail customised purchase options to meet your specific research requirements.

Custom Tailored Services

Delvens. offers transformed research reports where syndicated reports are not sufficient to provide solutions to your business.

Subscription Model

Get latest and trending updates throughout the year on the reports you buy.